Key points are not available for this paper at this time.
-mutated AML, mechanisms of venetoclax/BCL-2 inhibitor resistance in this molecular subset, and emerging strategies to potentially overcome this deficiency to guide therapeutic management for a population of patients who are in critical need of progress.
Iqbal et al. (Wed,) studied this question.